ICML 2023 | BOVen regimen for previously untreated CLL: long-term follow-up and MRD kinetics
Jacob Soumerai, MD, Massachusetts General Hospital, Boston, MA, shares the results from a long-term follow-up of a multicenter Phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia (CLL; NCT03824483). During the study, patients could discontinue treatment if they achieved undetectable measurable residual disease (uMRD) in both blood and bone marrow. The long-term follow-up (median 40 months) assessed the durability of patient responses to treatment, including progression-free survival (PFS) and MRD-free survival. Dr Soumerai explains the meaning of delta-MRD400, a measure of MRD kinetics, and shares that achieving delta-MRD400 was highly associated with prolonged MRD-free survival. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
